Source: Annual Congress 2010 - PG23 Postgraduate Course: Case and problem-based multimodal treatment in thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
G. Massard (Strasbourg, France). Indication and results of surgery in stage III NSCLC. Annual Congress 2010 - PG23 Postgraduate Course: Case and problem-based multimodal treatment in thoracic oncology

Member's Comments

No comment yet.

Related content which might interest you: Induction treatment prior to surgery in stage III NSCLC Source: Annual Congress 2010 - PG23 Postgraduate Course: Case and problem-based multimodal treatment in thoracic oncology Year: 2010 Radiochemotherapy in stage III NSCLC Source: Annual Congress 2010 - PG23 Postgraduate Course: Case and problem-based multimodal treatment in thoracic oncology Year: 2010 Intraoperative photodinamic therapy as a part of combined radical treatment for stage III NSCLC Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 Chemoradiotherapy with or without surgical resection for stage III NSCLC Source: Breathe 2010; 6: 275 Year: 2010 Postoperative adjuvant treatment in stage III NSCLC Source: Eur Respir J 2007; 30: Suppl. 51, 434s Year: 2007 Stage IIIA/B NSCLC: long-term results of induction chemotherapy and surgery Source: ISSN=ISSN 1810-6838, ISBN=, page=279 Year: 2008 Prerequisites, potential and limits of thoracic surgery with curative intent for stage III NSCLC Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease Year: 2019 Is there any survival benefit of surgery after neoadjuvant chemoradiotherapy and persisting pn2/3 in stage III NSCLC? Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009 NSCLC stage IV Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? Source: ERJ Open Res, 6 (1) 00159-2019; 10.1183/23120541.00159-2019 Year: 2020 Modern radiotherapy as a curative treatment modality for stage III NSCLC Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease Year: 2019 Indcution chemotherapy and radiotherapy vs. induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97 Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006 Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA Source: Eur Respir Rev 2015; 24: 340-355 Year: 2015 Improved survival associated with neoadjuvant chemoradiation and surgery vs other means of treatment for NSCLC N2 patients (clinical stage IIIa and IIIb) Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Survival of patients after complete surgical resection in NSCLC stage IV with solitary metastases Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011